Cargando…
MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2
In this study, we examined the role of the miRNA miR-770-5p in cisplatin chemotherapy resistance in ovarian cancer (OVC) patients. miR-770-5p expression was reduced in platinum-resistant patients. Using a 6.128-fold in expression as the cutoff value, miR-770-5p expression served as a prognostic biom...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288183/ https://www.ncbi.nlm.nih.gov/pubmed/27449101 http://dx.doi.org/10.18632/oncotarget.10736 |
_version_ | 1782504282743898112 |
---|---|
author | Zhao, Henan Yu, Xiaotang Ding, Yanfang Zhao, Jinyao Wang, Guang Wu, Xian Jiang, Jiyong Peng, Chun Guo, Gordon Zhuo Cui, Shiying |
author_facet | Zhao, Henan Yu, Xiaotang Ding, Yanfang Zhao, Jinyao Wang, Guang Wu, Xian Jiang, Jiyong Peng, Chun Guo, Gordon Zhuo Cui, Shiying |
author_sort | Zhao, Henan |
collection | PubMed |
description | In this study, we examined the role of the miRNA miR-770-5p in cisplatin chemotherapy resistance in ovarian cancer (OVC) patients. miR-770-5p expression was reduced in platinum-resistant patients. Using a 6.128-fold in expression as the cutoff value, miR-770-5p expression served as a prognostic biomarker and predicted the response to cisplatin treatment and survival among OVC patients. Overexpression of miR-770-5p in vitro reduced survival in chemoresistant cell lines after cisplatin treatment. ERCC2, a target gene of miR-770-5p that participates in the NER system, was negatively regulated by miR-770-5p. siRNA-mediated silencing of ERCC2 reversed the inhibition of apoptosis resulting from miR-770-5p downreglation in A2780S cells. A comet assay confirmed that this restoration of cisplatin chemosensitivity was due to the inhibition of DNA repair. These findings suggest that endogenous miR-770-5p may function as an anti-oncogene and promote chemosensitivity in OVC, at least in part by downregulating ERCC2. miR-770-5p may therefore be a useful biomarker for predicting chemosensitivity to cisplatin in OVC patients and improve the selection of effective, more personalized, treatment strategies. |
format | Online Article Text |
id | pubmed-5288183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-52881832017-02-07 MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2 Zhao, Henan Yu, Xiaotang Ding, Yanfang Zhao, Jinyao Wang, Guang Wu, Xian Jiang, Jiyong Peng, Chun Guo, Gordon Zhuo Cui, Shiying Oncotarget Research Paper In this study, we examined the role of the miRNA miR-770-5p in cisplatin chemotherapy resistance in ovarian cancer (OVC) patients. miR-770-5p expression was reduced in platinum-resistant patients. Using a 6.128-fold in expression as the cutoff value, miR-770-5p expression served as a prognostic biomarker and predicted the response to cisplatin treatment and survival among OVC patients. Overexpression of miR-770-5p in vitro reduced survival in chemoresistant cell lines after cisplatin treatment. ERCC2, a target gene of miR-770-5p that participates in the NER system, was negatively regulated by miR-770-5p. siRNA-mediated silencing of ERCC2 reversed the inhibition of apoptosis resulting from miR-770-5p downreglation in A2780S cells. A comet assay confirmed that this restoration of cisplatin chemosensitivity was due to the inhibition of DNA repair. These findings suggest that endogenous miR-770-5p may function as an anti-oncogene and promote chemosensitivity in OVC, at least in part by downregulating ERCC2. miR-770-5p may therefore be a useful biomarker for predicting chemosensitivity to cisplatin in OVC patients and improve the selection of effective, more personalized, treatment strategies. Impact Journals LLC 2016-07-20 /pmc/articles/PMC5288183/ /pubmed/27449101 http://dx.doi.org/10.18632/oncotarget.10736 Text en Copyright: © 2016 Zhao et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Zhao, Henan Yu, Xiaotang Ding, Yanfang Zhao, Jinyao Wang, Guang Wu, Xian Jiang, Jiyong Peng, Chun Guo, Gordon Zhuo Cui, Shiying MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2 |
title | MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2 |
title_full | MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2 |
title_fullStr | MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2 |
title_full_unstemmed | MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2 |
title_short | MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2 |
title_sort | mir-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ercc2 |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288183/ https://www.ncbi.nlm.nih.gov/pubmed/27449101 http://dx.doi.org/10.18632/oncotarget.10736 |
work_keys_str_mv | AT zhaohenan mir7705pinhibitscisplatinchemoresistanceinhumanovariancancerbytargetingercc2 AT yuxiaotang mir7705pinhibitscisplatinchemoresistanceinhumanovariancancerbytargetingercc2 AT dingyanfang mir7705pinhibitscisplatinchemoresistanceinhumanovariancancerbytargetingercc2 AT zhaojinyao mir7705pinhibitscisplatinchemoresistanceinhumanovariancancerbytargetingercc2 AT wangguang mir7705pinhibitscisplatinchemoresistanceinhumanovariancancerbytargetingercc2 AT wuxian mir7705pinhibitscisplatinchemoresistanceinhumanovariancancerbytargetingercc2 AT jiangjiyong mir7705pinhibitscisplatinchemoresistanceinhumanovariancancerbytargetingercc2 AT pengchun mir7705pinhibitscisplatinchemoresistanceinhumanovariancancerbytargetingercc2 AT guogordonzhuo mir7705pinhibitscisplatinchemoresistanceinhumanovariancancerbytargetingercc2 AT cuishiying mir7705pinhibitscisplatinchemoresistanceinhumanovariancancerbytargetingercc2 |